Here’s a roundup of companies announcing mergers, acquisitions and divestitures.

• PerkinElmer acquires Germany-based Chemagen Biopolymer-Technologie
  PerkinElmer Inc. (NYSE:PKI) acquired chemagen Biopolymer-Technologie AG, a key player in the field of automated nucleic acid isolation, as part of the its strategy to advance its offerings to the molecular diagnostics and research markets. “The addition of chemagen’s complementary products to PerkinElmer’s portfolio will provide the Company with robust platforms and solutions to meet the needs of the rapidly evolving molecular diagnostics market. The hardware and reagent capabilities brought by chemagen include a total solution in nucleic acid sample preparation, with automation-enabling features that can power high throughput applications in research, screening, and diagnostics,” PerkinElmer Chief scientific officer Daniel Marshak said in prepared remarks.
  Read more
• FTC grants early termination of waiting period under Hart-Scott-Rodino Act for Novartis’ Genoptix takeover
  Genoptix, Inc. (NSDQ:GXDX) announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended applicable to the cash tender offer by Novartis AG (NYSE:NVS) to purchase all outstanding shares of common stock of Genoptix at $25.00 per share. The termination of the HSR Act waiting period satisfies one of the conditions necessary for the consummation of the tender offer. The tender offer is scheduled to expire at 12:00 midnight, New York City time, on Feb. 25, 2011 (which is the end of the day on February 25, 2011), unless the tender offer is extended. Consummation of the tender offer remains subject to other customary conditions, including the tender of a majority of the outstanding shares of Genoptix’s common stock, determined on a fully diluted basis.
  Read more
• Microsulis sells microwave endometrial ablation to Hologic
  Microsulis Medical Ltd. announced that it has exclusively licensed to Hologic Inc. (NSDQ:HOLX) all rights to its microwave technology in the gynecology and female urology fields of use. “Through the sale of our MEA platform to Hologic, we not only open our microwave technology to the most capable device developer in the woman’s health space, but we release the value of MEA to underpin the commercialization phase of our MTA device.” Microsulis CEO Stuart McIntyre said in prepared remarks. “Hologic has the capability and market leadership needed to release the potential of our microwave technology to treat various female urological and gynecological conditions. There is no better company to nurture the technology in the woman’s health space.”
  Read more
• Vitalitec acquires ENCLOSE II anastomosis assist device
  Vitalitec International Inc., of Plymouth, Mass., is pleased to announce the acquisition of the ENCLOSE II Anastomosis Assist Device from Novare Surgical Systems Inc. The ENCLOSE II Anastomosis Assist Device was developed by Dr. Thomas Fogarty, and is designed to assist surgeons in performing “off pump” Coronary Artery Bypass Procedures.
  Read more
• Cantel Medical acquires sterilization monitoring biz of ConFirm
  Cantel Medical Corp. (NYSE:CMN), through its Crosstex International subsidiary, has further expanded its infection prevention and control business by purchasing the sterilization monitoring business of ConFirm Monitoring Systems, Inc. Based in Denver, Colorado, ConFirm is one of the leading providers of biological monitoring services in North America. ConFirm offers both a mail-in service and in-office spore test kits for healthcare professionals to verify the performance of their sterilizers in accordance with industry guidelines for daily or weekly testing.
  Read more